Department of Thoracic Surgery, West China Hospital, Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, Sichuan, China.
West China School of Medicine, Sichuan University, No. 37, Guoxue Alley, Chengdu, 610041, Sichuan, China.
World J Surg Oncol. 2022 Apr 30;20(1):140. doi: 10.1186/s12957-022-02603-4.
Pulmonary sclerosing pneumocytoma is a kind of rare benign pulmonary tumor with potential malignancy. The clinical features, risk factors for prognosis, and optimal treatment have not been identified yet. This study aimed to investigate the clinical features and prognosis of pulmonary sclerosing pneumocytoma.
We retrospectively performed a review of pulmonary sclerosing pneumocytoma patients in West China Hospital from 2009 to 2019. The basic characteristics, treatment regimens, operation detail, postoperative variables, and follow-up time were recorded for each case. Differences in features between patients undergoing lobectomy and segmentectomy were compared. We also performed a case review and summarized reported clinical features in former studies.
Altogether 61 pulmonary sclerosing pneumocytoma patients were retrospectively reviewed. Fifty-six patients were female and 5 were male. The patients' median age was 51 (23-73). Seven (11.48%) patients had smoking history. Twenty tumors were located in the right lung [upper lobe (n = 7), middle (n = 2), and lower (n = 11)] and 41 in the left [upper (n = 12) and lower (n = 29)]. The median tumor size was 2 (0.9-7) cm. Thirty-six (59.02%) patients underwent sublobectomy (segmentectomy or wedge resection) whereas 25 (40.98%) underwent lobectomy. All patients recovered uneventfully, and no perioperative mortality was identified. Sublobectomy showed a trend towards reduced chest tube duration and shorter postoperative hospital stays compared with lobectomy.
The findings showed good prognosis of pulmonary sclerosing pneumocytoma and proved its benign characteristics. Sublobectomy showed advanced efficacy regarding chest tube duration and postoperative hospital stay compared with lobectomy.
肺硬化性血管瘤是一种罕见的具有潜在恶性的良性肺肿瘤。其临床特征、预后危险因素和最佳治疗方法尚未确定。本研究旨在探讨肺硬化性血管瘤的临床特征和预后。
我们回顾性分析了 2009 年至 2019 年期间在华西医院就诊的肺硬化性血管瘤患者。记录了每位患者的基本特征、治疗方案、手术细节、术后变量和随访时间。比较了行肺叶切除术和节段切除术患者的特征差异。我们还进行了病例回顾，并总结了以前研究中报告的临床特征。
共回顾了 61 例肺硬化性血管瘤患者。其中 56 例为女性，5 例为男性。患者的中位年龄为 51 岁（23-73 岁）。7 例（11.48%）有吸烟史。20 个肿瘤位于右肺[上叶（n=7）、中叶（n=2）和下叶（n=11）]，41 个位于左肺[上叶（n=12）和下叶（n=29）]。肿瘤大小中位数为 2cm（0.9-7cm）。36 例（59.02%）患者行亚肺叶切除术（节段切除术或楔形切除术），25 例（40.98%）患者行肺叶切除术。所有患者均顺利康复，无围手术期死亡。与肺叶切除术相比，亚肺叶切除术在胸腔引流管持续时间和术后住院时间方面显示出降低的趋势。
研究结果显示肺硬化性血管瘤预后良好，证实其为良性特征。与肺叶切除术相比，亚肺叶切除术在胸腔引流管持续时间和术后住院时间方面具有优势。
